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We have previously demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) activates human T-cell leukemia virus
type-I long terminal repeat (LTR) in Jurkat cells by a protein kinase C (PKC)-independent mechanism involving a posttrans-
lational activation of Sp1 binding to an Sp1 site located within the Ets responsive region-1 (ERR-1). By employing the PKC
inhibitor, bisindolylmaleimide I and cotransfecting the reporter LTR construct with a vector expressing PKC-a, we demon-
strated, in the present study, that this effect of TPA was not only independent of, but actually antagonized by, PKC.
Electrophoretic mobility shift assays together with antibody-mediated supershift and immuno-coprecipitation analyses,
revealed that the posttranslational activation of Sp1 was exerted by inducing the formation of Sp1-p53 heterocomplex
capable of binding to the Sp1 site in ERR-1. Furthermore, we demonstrated that Jurkat cells contain both wild-type (w.t.) and mutant
forms of p53 and we detected both of them in this complex at variable combinations; some molecules of the complex contained
either the w.t. or the mutant p53 separately, whereas others contained the two of them together. Finally, we showed that the
Sp1-p53 complexes could bind also to an Sp1 site present in the promoter of another gene such as the cyclin-dependent kinase
inhibitor p21WAF-1, but not to consensus recognition sequences of the w.t. p53. Therefore, we speculate that there might be several
other PKC-independent biological effects of TPA which result from interaction of such Sp1-p53 complexes with Sp1 recognition
sites residing in the promoters of a wide variety of cellular and viral genes. © 2001 Academic Press
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(INTRODUCTION
Human T-cell leukemia virus type-I (HTLV-I) has been
implicated with the etiology of adult T-cell leukemia
(ATL), tropical spastic paraparesis/HTLV-I associated
myelopathy (TSP/HAM), and certain other clinical disor-
ders (Uchiyama, 1997). However, following infection, this
virus enters into a latent state, rendering the infected
individuals seropositive asymptomatic carriers, and only
a small percentage of these carriers may, eventually,
develop one of the HTLV-I-related diseases 20–40 years
later (Aboud et al., 1993; Cann and Chen, 1997). Although
the pathogenic mechanism of this virus is not yet com-
pletely clear, the viral transactivator Tax protein is widely
regarded as a key element in this mechanism, due to its
multiple effects on a variety of cellular transcription (Arm-
strong et al., 1993; Li and Gaynor, 1999; Li et al., 1999;
Mesnar and Devaux, 1999) and cell-cycle controlling
(Harhaj et al., 1999; Mesnar and Devaux, 1999; Ressler et
l., 1997; Tsukahara et al., 1999) factors and because of
1 To whom reprint requests should be addressed. Fax: 011-972-7-
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10ts interference with DNA repair (Cereseto et al., 1996;
eang et al., 1990; Kao and Marriott, 1999; Philpott and
uehring, 1999; Ressler et al., 1997; Uittenbogaard et al.,
994). With these pleiotropic effects Tax may transform
TLV-I-infected cells (Grassmann et al., 1989; Tanaka et
l., 1990) and set them into uncontrolled replication
Grassmann et al., 1992; Harhaj et al., 1999; Mesnar and
Devaux, 1999; Robek and Ratner, 1999) and genetic in-
stability (Maruyama et al., 1992, 1996; Miyake et al.,
1999). However, during the latent period, viral gene ex-
pression in the carriers’ infected cells is extremely low
(Brauweiler et al., 1995; Kinoshita et al., 1989) and con-
sequently the level of Tax protein is, plausibly, below the
pathogenically effective threshold. Therefore, it is con-
ceivable that generating an HTLV-I-related disease
would require an activation of the latent virus to elevate
the level of this protein. Thus, investigation of exogenous
or intrinsic factors capable of initiating Tax-independent
HTLV-I expression is of particular importance for a better
understanding of the first step of activation of the dor-
mant virus and its transition from the asymptomatic la-
tency to its pathologically active phase.
Phorbol and diterpen esters are examples of exoge-
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11Sp1-p53 COMPLEX AND HTLV-I LTR ACTIVATION BY TPAnous agents that have been shown to activate the ex-
pression of HTLV-I and reporter genes driven by its long
terminal repeat (LTR) in the absence of Tax protein
Aboud et al., 1993; Carter and Blakeslee, 1989; Fujii et
l., 1987; Mor-Vaknin et al., 1997; Nakao et al., 1984;
adonovich and Jean, 1989; Torgeman et al., 1999).
hese compounds are plant products (Matsuda et al.,
986; Nakao et al., 1984; Touraine et al., 1977) potentially
ccessible to human contact or consumption. Therefore,
2-O-tetradecanoylphorbol-13-acetate (TPA), the most in-
ensively studied representative of these compounds,
ay serve as a model for investigating possible mech-
nisms of activation of the latent HTLV-I.
TPA is a potent protein kinase C (PKC) activator (Jaken,
990). There are at least 12 PKC isoenzymes, which
egulate a wide variety of biochemical pathways in cells
Coussens et al., 1986; Mellor and Parker, 1998) and
herefore most of the biological effects of TPA have been
ttributed to PKC activation (Jaken, 1990). Yet. we have
reviously shown that, although prolonged exposure of
urkat cells to TPA severely depletes them from the
PA-responsive PKC isoenzymes, the expression of a
eporter HTLV-I LTR construct is highly stimulated when
ransfected into such PKC-depleted cells (Mor-Vaknin et
l., 1997). We have also noted that addition of PKC inhib-
tors prior to TPA does not abrogate this stimulation
Mor-Vaknin et al., 1997; Torgeman et al., 1999). This
xcludes the possibility that the delayed effect of TPA is
ediated by a long lasting factor that has been activated
y PKC prior to its depletion. Subsequent experiments
ave indicated that this effect is exerted through a post-
ranslational activation of the Sp1 transcription factor
inding to an Sp1 recognition site located within the Ets
esponsive region 1 (ERR-1) of the viral LTR (Torgeman et
l., 1999).
FIG. 1. Effect of TPA, BI, and PKCa on HTLV-I LTR-CAT expression.
ndicated times, were transfected with HTLV-I LTR-CAT construct. (B) Th
expressing vector into the Jurkat cells under the specified conditions. Wh
1 h before TPA. CAT activity was measured 48 h after transfection, normali
activity detected in the untreated control cells. The illustrated data represThe present study provides evidence that the effect of
PA on HTLV-I LTR expression, as well as the activationf Sp1, are not only independent of PKC, but are actually
ntagonized by its activity. Furthermore, this study dem-
nstrates that the posttranslational activation of Sp1 is
xerted by inducing the formation of Sp1-p53 heterocom-
lex. Notably, Jurkat and certain other T-cell lines contain
oth wild-type (w.t.) and mutant forms of p53 protein
Cheng and Haas, 1990; Gualberto and Baldwin, 1995;
ualberto et al., 1995) and our present experiments in-
icate that both forms participate in the formation of this
eterocomplex.
RESULTS
KC antagonizes the TPA stimulatory effect on HTLV-I
TR expression and on the nuclear protein binding to
he Sp1 site in ERR-1
We have previously shown that TPA enhances HTLV-I
TR expression in Jurkat cells by a PKC-independent
echanism (Mor-Vaknin et al., 1997; Torgeman et al.,
1999). To further characterize this effect, it was subjected
to a more detailed time-course analysis in the presence
and absence of the PKC inhibitor bisindolylmaleimide
(BI) (Toullec et al., 1991), which proved, in our previous
study (Torgeman et al., 1999), to be highly efficient as an
in situ PKC inhibitor. Figure 1A shows no or very little
stimulation of HTLV-I LTR-CAT expression in Jurkat cells
transfected with this construct after 4 or 12 h of TPA
treatment, i.e., when active PKC was declining but still
present in the cells (see Mor-Vaknin et al., 1997, for
detailed kinetics of the TPA-induced PKC downregulation
in these cells). Notably, LTR expression at these time
points was significantly enhanced when BI was added
1 h before TPA. However, when this construct was trans-
fected after longer TPA pretreatment (i.e., when the cells
were already depleted of PKC), its expression progres-
kat cells, pretreated with TPA alone (F) or with TPA 1 BI (E) for the
-I LTR-CAT construct was transfected alone or together with the PKC-a
cated, TPA treatment was for 72 h before transfection and BI was added
he protein concentration of each cell extract, and presented as fold of the
average of three repeated experiments 6 standard deviation.(A) Jur
e HTLV
ere indisively increased as the duration of the TPA pretreatment
increased. Moreover, no significant effect of BI was de-
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12 TORGEMAN ET AL.tected after such extended TPA pretreatment. It is, thus,
evident that the LTR stimulation by TPA is more efficient
when PKC activity is either diminished by a specific
inhibitor or depleted by a prolonged exposure to this
phorbol ester. This notion, that active PKC antagonizes
this stimulatory effect of TPA, was further tested by co-
transfecting the LTR-CAT construct with a vector ex-
pressing constitutively active PKC-a (pZLPKC-a), which
s one of the major PKC isoenzyme in Jurkat cells (Mor-
aknin et al., 1997). Figure 1B shows that this exogenous
KC markedly reduced the basal LTR expression in TPA-
ntreated control cells and completely abolished its
timulation by a prolonged TPA pretreatment. It is also
hown that both of these inhibitory effects were dimin-
shed by the inhibitor BI, thus assuring that they were
nduced by the exogenous PKC.
Our recent study (Torgeman et al., 1999) has also
hown that nuclear proteins of Jurkat cells form three
istinct complexes with an oligonucleotide carrying the
RR-1 sequence (see Fig. 2A for a schematic presenta-
ion of ERR-1) that we have designated as I, II, and III
see Figs. 2B and 2C). Further experiments have shown
hat complex I is preferentially stimulated by prolonged
PA treatment, whereas complex II is stimulated to a
uch lower extent and complex III is unaffected. Com-
etitive electrophoretic mobility shift assay has revealed
hat complex I is formed on the Sp1 site and complex II
on the pets site present within ERR-1, and subsequent
deletion functional analysis of ERR-1 have demonstrated
that the Sp1 site (i.e., complex I) is the element mediating
the LTR stimulation in the PKC-depleted cells (Torgeman
et al., 1999). The significance of the moderate complex II
elevation has not been clarified yet. In view of these data
and the PKC antagonism against LTR stimulation by the
prolonged TPA treatment illustrated in Fig. 1, it was im-
portant to assess the role of PKC in complex I formation.
For this purpose we compared, in the next experiment,
the effect of brief TPA treatments (4 and 12 h) on this
complex formation to that of prolonged treatments (24
and 48 h). Figure 2B indicates that while the prolonged
treatments profoundly stimulated complex I formation,
the brief treatments elicited negligible effect, unless they
were done in the presence of the PKC inhibitor, BI. This
finding strongly suggests that PKC activity antagonizes
the stimulatory effect of TPA on HTLV-I LTR expression
by interfering with complex I formation.
An additional indication for this antagonism emerged
from the experiment presented in Fig. 2C, which demon-
strated that 72-h treatment of the cells with the cal-
cineurin inhibitor, cyclosporin A (CSA), markedly stimu-
lated complex I formation, but when added together with
PA, their combined effect was considerably lower than
hat of each of them alone. Calcineurin dephosphory-
ates serine/threonine targets of various serine/threo-
ine protein kinases, including PKC (Scott, 1997). There-
ore, these results suggest that preventing dephosphor-lation of certain serine/threonine targets of a non-PKC
rotein kinases stimulates complex I formation, whereas
reserving the phosphorylation of certain serine/threo-
ine targets of PKC rather inhibits this complex forma-
ion. Moreover, it appears from these results that the
egative effect of the PKC-mediated phosphorylation is
ominant over the stimulatory phosphorylation by the
on-PKC protein kinases. Consistent with this interpre-
ation, Fig. 2C shows that when the PKC-mediated phos-
horylation was blocked by BI, the joint effect of CSA and
PA became cumulative.
A similar TPA-induced PKC-independent stimulation of
TLV-I LTR expression (Fig. 3A) and complex I formation
(Fig. 3B) was also observed in two other T-cell lines,
SupT1 and CEM3174, indicating that this phenomenon
was not unique to Jurkat cells.
Complex I is formed by Sp1 and p53 proteins
We have previously shown that complex I formation is
stimulated by TPA through a posttranslational activation
of Sp1 binding to the Sp1 site in ERR1 (Torgeman et al.,
1999). Other laboratories have demonstrated that under
certain conditions some missense mutants of p53 pro-
tein associate with the Sp1 protein to form a complex
that activates the expression of HIV-1 LTR and certain
other promoters by binding to their Sp1 recognition sites
(Borellini and Glazer, 1993; Gualberto and Baldwin, 1995;
Ohlsson et al., 1998; Sawaya et al., 1998). There are also
indications for a similar association between Sp1 and
w.t. p53 protein (Gualberto and Baldwin, 1995; Gualberto
et al., 1995; Sawaya et al., 1998). Therefore, we investi-
gated whether p53 was involved in the TPA-induced
posttranslational Sp1 activation. This was done by ana-
lyzing the effect of anti-Sp1 and anti-p53 (pAb421) anti-
bodies on complex I electrophoretic mobility. Figure 4A
shows that each of these antibodies supershifted the
migration of this complex, while completely eliminating the
original band I (lanes 3 and 4, respectively). This finding
indicates that band I represents a single complex, contain-
ing both the Sp1 and the p53 proteins together, rather than
a mixture of two distinct but similarly migrating complexes,
one that contains only Sp1 and the other only p53. This
conclusion was further supported by the observation that a
combination of these two antibodies supershifted complex
I significantly further as a single complex (band Ic in lane 5)
rather than separating it into the two differently migrating
supershifted complexes seen in lane 3 and 4. The speci-
ficity of this supershift was confirmed by the failure of two
irrelevant antibodies, anti-albumin (lane 2) and anti-c-Jun
(lane 6), to affect complex I migration.
Complex I contains both wild-type and mutant forms
of p53 proteinJurkat cells, as well as certain other T-cell lines, have
been reported to contain both w.t. and mutant forms of
r 72 h
The da
13Sp1-p53 COMPLEX AND HTLV-I LTR ACTIVATION BY TPAp53 protein (Cheng and Haas, 1990; Gualberto and Bald-
win, 1995; Gualberto et al., 1995). The presence of both
FIG. 2. Effect of TPA, CSA, and BI on the binding of nuclear proteins
sequence of ERR-1 and the location of the binding sites of various t
represent the position of the nucleotides in the viral LTR relatively to th
with TPA alone or with TPA 1 BI for the indicated times, were analyzed
with TPA or TPA 1 CSA in the absence (left) or presence (right) of BI fo
were tested for protein binding 32P-labeled ERR-1 oligonucleotide. (D)p53 forms in our Jurkat cells was confirmed by reacting
their nuclear extract with either pAb1620 or pAb240 an-tibodies (which exclusively recognize only w.t. and only
mutant p53, respectively) and by subjecting the immuno-
at cells to ERR-1. (A) Schematic presentation of ERR-1. The nucleotide
ption factors known to interact with ERR-1 are shown. The numbers
ription starting point. (B) Nuclear extracts, prepared from cells treated
ein binding to P32-labeled ERR-1oligonucleotide. (C) Cells were treated
(BI was added 1 h before the other agents), and their nuclear extracts
ta in B and C are schematically summarized.of Jurk
ranscri
e transc
for protprecipitates to Western blot analysis with rabbit poly-
clonal anti p53 antibodies. Notably, a comparable level of
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14 TORGEMAN ET AL.both p53 forms was detected in the nuclear extract of
TPA-treated and untreated cells (Fig. 4C). Since both
p53 forms can potentially associate with Sp1 (Gual-
berto and Baldwin, 1995; Gualberto et al., 1995;
awaya et al., 1998), it was of interest to find out which
f them participated in the TPA-induced complex I
ormation. For this purpose, we performed supershift
nalysis of complex I with pAb1620 and pAb240 anti-
odies. Figure 4B illustrates that each of these two
ntibodies only partially supershifted complex I (lanes
and 4). Furthermore, in addition to the remaining
and I, each of these antibodies formed two new
ands, IA and IB. This suggests that both forms of p53
articipate in forming a mixture of Sp1-p53 complexes
ith variable w.t./mutant p53 combinations. Some of
hese complexes seem to contain Sp1 with only w.t.
53 molecules and therefore are maximally super-
hifted by pAb1620 antibodies (band IB in lane 4), but
re not supershifted at all by pAb240 antibodies (band
in lane 3). Others contain Sp1 with only mutant p53
olecules and therefore are maximally supershifted
y the pAb240 antibodies (band IB in lane 3), but not at
ll by the pAb1620 antibodies (band I in lane 4). The
emaining complexes contain Sp1 associated with
oth w.t. and mutant p53 molecules together. Such
omplexes can bind fewer molecules of each of these
ntibodies and are therefore intermediately super-
hifted by both pAb240 (band IA in lanes 3) and
Ab1620 (band IA in lanes 4). As predicted, all these
eterocomplexes were maximally supershifted by
FIG. 3. Effect of TPA and BI on HTLV-I LTR-CAT expression and on
nuclear protein binding to ERR-1 in SupT1 and CEM3174 cells. (A)
SupT1 (left) and CEM3174 (right) cells pretreated with TPA alone or
with TPA 1 BI for the indicate times were transfected with HTLV-I
LTR-CAT construct and assayed for CAT activity 48 h after transfection
as in Fig. 1A. (B) SupT1 (left) and CEM3174 (right) cells were treated for
72 h with TPA alone (lanes 2 and 5) or with TPA 1 BI (lanes 3 and 6).
ntreated cells (lanes 1 and 4) served as control. Nuclear extracts
repared from these cells were tested for protein binding to 32P-labeled
RR-1 oligonucleotide.Ab421 antibodies, which recognize both w.t. and mu-
ant p53 (band IB in lane 2).
b
aTPA induces the Sp1-p53 association independently
of their binding to DNA
Next, we elucidated whether Sp1 and p53 proteins
were interdependent on each other for their binding to
the same Sp1 site. For this purpose, aliquots of the
nuclear extract of Jurkat cells, treated with TPA for 72 h,
were incubated with the pAb421 anti-p53 or with the
anti-Sp1 antibodies and after removal of the immunopre-
cipitates the supernatants were tested for binding to
ERR-1 oligonucleotide. If Sp1 and p53 could bind the Sp1
site independently of each other, each of these superna-
tants would be expected to form an electrophoretically
faster complex in place of the original complex I. How-
ever, Fig. 5A excludes this possibility by showing that
both supernatants lost, indeed, their ability to form the
original complex I, but did not form any new complex
nstead (see lane 3 for the Sp1-free supernatant and lane
for the p53-free supernatant). Both supernatants re-
ained their ability to form the other two complexes, thus
erifying the specificity of the immunoprecipitation. This
pecificity was further confirmed by the failure of the two
rrelevant antibodies, the anti-albumin (lane 2) and the
nti-c-Jun (lane 5) to affect the formation of any of the
hree complexes.
To determine whether the association between Sp1
nd p53 requires their binding to the target DNA, the
mmunoprecipitates obtained in the experiment depicted
n Fig. 5A were subjected to Western blot analysis. As
hown in Fig. 5B, anti Sp1 antibodies readily detected
he 97-kDa Sp1 protein in the immunoprecipitate pulled
own by pAb421 antibodies from the nuclear extract of
FIG. 4. Supershift analysis of complex I and detection of w.t. and
mutant p53 in nuclear extract of Jurkat cells. The nuclear extract of cells
treated with TPA for 72 h was reacted with 32P-labeled ERR-1 oligonu-
leotide in the presence of the following antibodies: (A) none (lane 1),
nti-albumin (lane 2), anti-Sp1 (lane 3), pAb421 which recognizes both
.t. and mutant p53 (lane 4), anti-Sp1 1 pAb421 (lane 5), and anti-c-Jun
lane 6); (B) none (lane 1), pAb421 anti-p53 (lane 2), pAb240 which
ecognizes only mutant p53 (lane 3), and pAb1620 which recognizes
nly w.t. p53 (lane 4). The resulting complexes were analyzed for their
el electrophoretic mobility. (C) Nuclear extracts of the TPA-treated
lane 1 and 2) and untreated (lane 3 and 4) cells were reacted with
Ab1620 (lane 1 and 3) or pAb240 (lane 2 and 4) antibodies and the
mmunoprecipitates were subjected to Western blot analysis with rab-
it anti-p53 polyclonal antibodies and peroxidase-conjugated mouse
ntibodies against rabbit IgG.
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15Sp1-p53 COMPLEX AND HTLV-I LTR ACTIVATION BY TPAthe TPA-treated cells (lane 1), whereas this protein was
below detectable level in the immunoprecipitate prepared
from TPA-untreated control cells (lane 2). Stripping the blot
from the anti Sp1 antibodies and reacting it with rabbit anti
p53 polyclonal antibodies revealed comparable p53-spe-
cific bands in both lanes (Fig. 5C). A reciprocal Western blot
analysis of the immunoprecipitates pulled down by the
mouse anti-Sp1 antibodies is illustrated in Fig. 5D. In this
analysis p53 protein was readily detected by rabbit anti-p53
antibodies in the immunoprecipitate of the TPA-treated
cells (lane 1) but not of the untreated control cells (lane 2).
Reacting this blot with anti Sp1 antibodies, after stripping it
from the anti-p53 antibodies, revealed comparable Sp1
specific bands in lanes 1 and 2 (Fig. 5E). Notably, semi-
quantitative Western analysis of the whole nuclear extracts
confirmed that exposure to TPA had no effect on the nu-
clear level of either Sp1 or p53 proteins (Fig. 6). This finding,
together with the coprecipitation results shown in Figs. 5B
and 5D, strongly suggests that TPA induces the Sp1/p53
association by a posttranslational event, independently of
their binding to DNA targets.
Sp1-p53 complex binds to consensus recognition
sites of Sp1 but not of w.t. p53
FIG. 5. Characterization of complex I formation by immuno-copre-
ipitation analysis. (A) Aliquots of the nuclear extract of Jurkat cell,
reated with TPA for 72 h, were reacted with the following antibodies:
one (lane 1), anti-albumin (lane 2), anti-Sp1 (lane 3), pAb421 anti-p53
lane 4), and anti-c-Jun (lane 5). The resulting immunoprecipitates were
emoved by protein A-bound Sepharose CL-4B beads and the super-
atants were tested for binding to 32P-labeled ERR-1 oligonucleotide.
B) The immunoprecipitates pulled down by the pA421 anti p53 anti-
odies from nuclear extracts of TPA-treated (72 h, lane 1) and untreated
lane 2) Jurkat cells were subjected to Western blot analysis with
ouse anti-Sp1 antibodies and peroxidase-conjugated rabbit anti-
ouse IgG antibodies. (C) The filter of B was stripped and reacted with
abbit anti-p53 antibodies and peroxidase-conjugated mouse anti-rab-
it IgG antibodies. (D) The immunoprecipitates, pulled down by the
ouse anti-Sp1 antibodies from nuclear extracts of the above TPA-
reated (lane 1) and untreated (lane 2) cells, were subjected to Western
lot analysis with rabbit polyclonal anti-p53 antibodies and peroxidase-
onjugated mouse antibodies against rabbit IgG. (E) The filter of D was
tripped and reacted with mouse anti-Sp1 antibodies and peroxidase-
onjugated rabbit anti-mouse IgG antibodies. Size markers are shown
t the left side of B and D and they apply also for C and E, respectively.Since some of the Sp1-p53 complexes formed in the
TPA-treated cells contain w.t. p53 protein, it was impor-tant to verify whether these complexes also bind to p53
consensus recognition sites and activate promoters con-
taining such sites. In the first experiment, the pG13-CAT
construct (which contains 13 copies of p53 consensus
recognition sequences) was transfected into Jurkat cells
pretreated for 72 h with TPA and to untreated control
cells. Figure 7A shows that the basal expression of this
construct in the untreated cells was extremely low. This
low expression can be attributed to the mutant p53
present in these cells, since it is well known that mutant
p53 negatively transdominates the transcriptional trans-
activation function of the w.t. p53 (Kerns et al., 1992).
urthermore, the expression of this construct was not
ffected at all by the TPA pretreatment (Fig. 7A). The
rivial possibility that the employed pG13-CAT construct
ight be defective was ruled out by showing that its
xpression was markedly stimulated when cotransfected
ith the w.t. p53-expressing pc53-SN3 vector (Fig. 7A).
herefore, these data strongly suggest that the TPA-
nduced Sp1-p53 complex does not activate gene ex-
ression through w.t. p53 consensus recognition sites.
his was further supported by demonstrating that an
ligonucleotide, carrying the w.t. p53 consensus recog-
ition sequence (p53, r.s.), could not compete out com-
lex I formation on ERR-1 probe (Fig. 7B, lane 2), neither
ould it form any complex with nuclear proteins of TPA-
reated or untreated cells (Fig. 7B, lanes 5 and 6). This
ligonucleotide proved, however, to be highly functional
n forming a specific complex with a purified w.t. p53
rotein (Fig. 7B, lane 7), thus ruling out the possibility that
t might have been defective. These data are consistent
ith other reports showing that under certain conditions,
.t. and mutant p53 proteins associate with certain other
ranscription factors and influence their specific activity
ather than conferring a p53 DNA-binding specificity on
he resulting complexes (Agarwal et al., 1998).
In contrast; Fig. 7B shows that excess of an oligonu-
leotide with the Sp1 site of the p21WAF-1 promoter (Sp1/
FIG. 6. Semiquantitative Western blot analysis of TPA effect on the
nuclear level of Sp1 and p53 proteins. The indicated quantities (100 and
200 mg protein) of nuclear extracts prepared from Jurkat cells after
treatment with TPA for the indicated times were subjected to Western
blot analysis with (A) anti-Sp1 or (B) pAb421 anti-p53 antibodies. Size
markers and purified Sp1 and p53 proteins (not shown) were run in
parallel in the corresponding gels.
c
a
-Sp1 an
16 TORGEMAN ET AL.WAF-1) specifically blocked only complex I formation on
the ERR-1 probe (lane 3), whereas excess of the ERR-1
oligonucleotide eliminated all the three bands formed on
this probe (lane 4). In addition, Fig. 7C shows that the
Sp1/WAF-1 oligonucleotide formed two complexes with
nuclear proteins of TPA treated cells (lane 1) and that
only the upper band was competed out by excess of the
ERR-1 oligonucleotide (lane 2). Moreover, this complex
was supershifted by anti Sp1 (lane 3) as well as by the
pAb421 anti p53 antibodies (lane 4). Together these data
suggest that the Sp1-p53 complex can bind to Sp1 con-
sensus recognition sites of various genes.
DISCUSSION
The present study demonstrated that the stimulatory
effect of TPA on HTLV-I LTR expression and complex I
formation on ERR-1 probe was not only independent of
PKC activity but was actually antagonized by this activity.
In addition, by employing the calcineurin inhibitor, CSA,
in various combinations with TPA and BI, we provided
evidence to suggest that certain non-PKC serine/threo-
nine protein kinase(s) stimulate complex I formation and
that this stimulation was also antagonized by PKC. Of
note in this context is our previously reported observa-
tion that the basal activity of protein kinase A (PKA),
present in cells in the absence of cAMP-stimulating
signals, is essential for the basal expression of HTLV-I
LTR (Turgeman and Aboud, 1998). It is tempting to spec-
ulate that the stimulation of LTR expression, noted when
the cells were exposed to CSA alone, might result from
FIG. 7. Effect of TPA on the expression of w.t. p53 responsive pro
recognition sites. (A) The pG13-CAT construct was transfected to Jurkat
pG13 promoter is functional and can be activated in these cells, the p
vector. (B) The nuclear extract of the TPA-treated cells was reacted wit
1) or with 50-fold molar excess of unlabeled p53, r.s. (lane 2), Sp1, WAF-1
of reacting 32P-labeled p53, r.s. oligonucleotide with the nuclear extra
omplex formed by purified w.t. p53 protein on p53, r.s. oligonucleoti
ntibodies. (C) The nuclear extract of the TPA-treated cells was reacted
of 50-fold molar excess of unlabeled ERR1 oligonucleotide (lane 2), anti
complexes were subjected to gel electrophoretic mobility analysis.preserving the phosphorylation mediated by this basal
PKA activity. We are currently investigating whether theeffective phosphorylated serine/threonine residues re-
side in the proteins comprising complex I or in a certain
other factor that indirectly affects this complex formation.
Supershift analysis with anti-Sp1 antibodies and the
pAb421 anti-p53 antibodies indicated that complex I con-
tains both Sp1 and p53 proteins. Jurkat and certain other
T-cell lines are heterozygous for p53 and produce both
w.t. and mutant forms of p53 protein (Cheng and Haas,
1990; Gualberto and Baldwin, 1995; Gualberto et al.,
1995). Further analysis of complex I, with antibodies
specifically recognizing only mutant (pAb240) or only w.t.
(pAb1620) p53, revealed that both p53 forms were
present in this complex at variable combinations. Inter-
estingly, the effect of TPA differs in this respect from
those of GM-CSF and TNF, which have been shown by
others to stimulate a selective association of Sp1 only
with mutant p53 (Borellini and Glazer, 1993; Gualberto
and Baldwin, 1995). However, in vitro experiments have
shown that association between Sp1 and w.t. p53 is also
possible (Kerns et al., 1992; Sawaya et al., 1998).
Immuno-coprecipitation analysis revealed that the
TPA-induced Sp1-p53 complex formation occurs inde-
pendently of the binding of these proteins to the target
DNA sequences. In addition, no significant TPA-induced
elevation could be detected in the level of either Sp1 or
any of the p53 forms, indicating that TPA stimulated the
formation of their heterocomplexes by a posttranslational
event. This finding is consistent with numerous studies
showing that the activity of Sp1 and p53 is regulated by
posttranslational events, such as phosphorylation
and examination of Sp1-p53 binding to w.t. p53 and Sp1 consensus
retreated for 72 h with TPA and to untreated control cells. To verify that
T construct was cotransfected with the w.t. p53-expressing pc53-SN3
beled ERR1 oligonucleotide without competitor oligonucleotides (lane
3), and ERR-1 (lane 4) oligonucleotides. Lanes 5 and 6 show the results
the TPA-treated and untreated cells, respectively. Lane 7 shows the
reas lane 8 shows a supershift of this complex by pAb421 anti p53
P-labeled Sp1, WAF-1 oligonucleotide alone (lane 1) or in the presence
tibodies (lane 3), and pA421 anti-p53 antibodies (lane 4). The resultingmoter
cells p
G13-CA
h 32P-la
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cts of
de, whe
with 32(Anderson, 1993; Baudier et al., 1992; Chernov et al.,
1998; Esposito et al., 1997; Legget et al., 1995; Milne et
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17Sp1-p53 COMPLEX AND HTLV-I LTR ACTIVATION BY TPAal., 1995; Zhang and Kim, 1997), dephosphorylation (Yan
et al., 1997; Zhang and Kim, 1997), and protein–protein
interactions (Borellini and Glazer, 1993; Chen et al., 1994;
Farmer et al., 1996; Gu et al., 1997; Gualberto and Bald-
win, 1995; Hansen et al., 1996; Lu and Levin, 1995; Mundt
et al., 1997; Ohlsson et al., 1998; Thut et al., 1995, 1997).
Gel-shift and competition analyses demonstrated that
the Sp1-p53 complex can bind to Sp1 sites but not to
consensus recognition sequences of the w.t. p53. Since
promoters of many cellular genes contain Sp1 binding
sites (Azizkhan et al., 1993), it is possible that at least
some of the cellular responses to TPA and other agents
capable of inducing Sp1-p53 complex formation (Borel-
lini and Glazer, 1993; Gualberto and Baldwin, 1995; Ohls-
son et al., 1998; Sawaya et al., 1998) are mediated by this
complex. In addition, this complex may explain cases
where genes lacking p53 binding sites have been found
to be activated by w.t. or mutant forms of p53 (Borellini
and Glazer, 1993; Gualberto and Baldwin, 1995; Ohlsson
et al., 1998). Also notable is our finding that Sp1-p53
complex binds to the Sp1 site of the p21WAF-1 promoter.
his gene is an immediate downstream target of the w.t.
53 and its transactivation by this tumor suppressor
eads to cell-cycle arrest which frequently precedes the
nset of apoptosis (El-Diery et al., 1994; Levin, 1997).
owever; p21WAF-1-mediated cell-cycle arrest has been
reported to occur also independently of w.t. p53 (Zeng
and El-Diery, 1996). It is quite possible that in some of
these cases p21WAF-1 activation is mediated by Sp1-p53
complex. Indeed in a parallel study (in preparation) we
have found that exposure of Jurkat cells to TPA induces
a temporary elevation of p21WAF-1 protein, leading to a
temporary cell-cycle arrest which is followed by apopto-
sis. Because of the presence of the mutant p53 in these
cells, which negatively transdominates the w.t. p53
(Kerns et al., 1992), it very likely that this p21WAF-1 elevation
was exerted though the binding of the Sp1-p53 complex
rather than through w.t. p53. In addition, we have noted
that a genotoxic agent, like cisplatin, also induces apo-
ptosis and HTLV-I LTR expression in these cells through
a similar Sp1-p53 complex (unpublished data). This may
suggest that environmental or/and intrinsic DNA damag-
ing agents and other factors capable of inducing cell-
cycle arrest and apoptosis might be involved in activat-
ing the latent virus in HTLV-I carriers. It is of interest to
mention in this context certain earlier reports demon-
strating that the viral Tax protein inhibits cell-cycle arrest
and apoptosis, whereas other studies have indicated
that Tax rather enhances the effect of cell-cycle arresting
and apoptosis inducing agents. However, the potential of
Tax to protect from cell-cycle arrest and apoptosis ap-
pears to be dominant in HTLV-I-transformed T-cells
(Mesnar and Devaux, 1999). It is, therefore, reasonable to
postulate that after activation of the latent virus in HTLV-I
carriers the emerging Tax protein acts to rescue the host
cells from the cell-cycle arrest and the apoptotic death
tinduced by the virus activating agents. In this manner
Tax may enable the subsequent stepwise progression of
these cells toward the HTLV-I-related adult T-cell leuke-
mia.
Finally, the ability of TPA to exert its stimulatory effect
on the LTR expression in the absence of Tax further
supports the view that this effect may serve as a model
for the mechanism of the latent virus activation in HTLV-I
carriers, since this activation is supposed to take place
in cells containing extremely low Tax level. Although we
ave found Tax to synergistically enhance the expres-
ion of HTLV-I LTR in cells subjected to prolonged TPA
retreatment (unpublished data), it is rather unlikely that
ax acts to enhance complex I formation on ERR-I, since
ax has been shown in two of our previous studies
Mor-Vaknin et al., 1997; Torgeman et al., 1999) to elicit
omparable stimulatory effects on w.t. LTR and ERR-1
acking mutant LTR.
MATERIALS AND METHODS
ells
The human T-cell lines Jurkat, SupT1, and CEM3174
mployed in this study were kindly provided by Dr. Irvin
. Y. Chen (UCLA, Los Angeles, CA). They were grown in
PM1–1640 medium supplemented with 10% fetal calf
erum and antibiotics.
ntibodies
Mouse monoclonal antibodies against Sp1, c-Jun, and
lbumin, rabbit polyclonal anti-p53, rabbit anti-mouse-
gG, and mouse anti rabbit-IgG antibodies were pur-
hased from Santa Cruz Biotechnology Inc., Santa Cruz,
A. Mouse anti-human p53 monoclonal antibodies
lones pAb421 (recognizing both w.t. and mutant forms of
53), pAb240 (recognizing only mutant forms of p53), and
Ab1620 (recognizing only w.t. p53) were a generous gift
rom Professor Varda Rotter (Weizman Institute of Sci-
nce, Rehovot, Israel).
lasmids
The plasmids used in this study were HTLV-I LTR-CAT
Mor-Vaknin et al., 1997), pG13-CAT expressing CAT
hrough a promoter containing 13 copies of the consen-
us binding sequence of the w.t. p53 protein (Kerns et al.,
992), pc53-SN3 expressing w.t. p53 through the hCMV
romoter (Kerns et al., 1992), and pZLPKC-a expressing
he PKC-a isenzyme through MoMuLV LTR (Eldar et al.,
990).
reatment with TPA, bisindolylmaleimide I, and
yclosporin A
Cells were suspended in complete medium at an ini-
5ial density of 3 3 10 cells/ml and TPA (50 nM, Sigma
Chemicals Israel Ltd., Holon, Israel) was added at differ-
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18 TORGEMAN ET AL.ent time intervals. Cells grown in parallel without TPA,
and harvested simultaneously with the TPA-treated cells
at the end of the experiment, served as a control to
monitor possible effect of the culture aging. When spec-
ified, 1 mm of the PKC inhibitor bisindolylmaleimide I
(Calbiochem, La Jolla, CA; Toullec et al., 1991) was added
1 h before TPA to ensure its penetration into the cells
before the TPA-induced PKC-activation took place. In
experiments with the calcineurin inhibitor, CSA (Sigma
Chemicals Israel Ltd.; Guerini, 1997), this drug (1 mg/ml)
as added either alone or simultaneously with TPA.
reparation of nuclear extracts
Cells (107) were washed twice with cold phosphate-
uffered saline and allowed to swell on ice for 10 min in
buffer containing 10 mM Hepes–KOH (pH 7.9), 1.5 mM
gCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM phenyl-
ethylsulfonylfluoride (PMSF), 10 mg/ml leupeptin, and
0 mg/ml aprotinin; NP-40 was then added (0.5% final
oncentration) and the suspension was vigorously vor-
exed for 10 s and briefly centrifuged at 14,000g. The
ellet was resuspended in a buffer containing 20 mM
epes–KOH (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM
gCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM
MSF, 10 mg/ml leupeptin, and 10 mg/ml aprotinin. This
uspension was allowed to stand on ice for 20 min and
hen centrifuged at 14,000g for 2 min. Protein concentra-
ion of the resulting supernatant was determined by the
io-Rad reagent and this extract was stored in small
liquots at 270°C.
lectrophoretic mobility shift assay (EMSA)
The following oligonucleotides were used in this
tudy: the complete ERR-1 sequence: 59-CCTCCGG-
AAGCCACCAAGAACCACCCATTTCCTCCCCATGTTTG-39
Bosselut et al., 1990; Gitlin et al., 1991), which was desig-
ated as ERR1; the Sp1 binding site from the p21WAF-1 gene
promoter 59-CTGGGCCCCGGGGAGGGCGGTCCCGGGC-
GGCGCG-39 (Biggs et al., 1996) that we designated as
Sp1/WAF-1 and the consensus w.t. p53 recognition se-
quence 59-GGACATGCCCGGGCATGTC-39 (Funk et al.,
1992) designated as p53/r.s.
The oligonucleotides, used as probes for DNA binding
assay of nuclear proteins, were labeled by filling in with
the Klenow fragment of DNA polymerase-I and
[a-32P]dCTP as detailed by Gitlin et al. (1991). The labeled
probe was added (1 ng, ;5 3 104 cpm) to a binding
eaction mixture (30 ml final volume) containing 15 mg
nuclear proteins, or 300 ng recombinant w.t. p53 protein
(kindly provided by Professor Moshe Oren from the Weiz-
man Institute of Science, Rehovot, Israel), 10 mM Tris–
HCl (pH 7.4), 100 mM KCl, 5 mM MgCl2, 1 mM dithiothre-
tol, 12.5% glycerol, 0.1% NP-40, and 3 mg poly(dI-dC). The
ixture was first pre-incubated on ice for 20 min beforedding the probe and further incubated at room temper-
ture for an additional 20 min after the probe addition.
For competition analysis, 50-fold molar excess of the
ompeting oligonucleotide over the labeled probe was
dded together with the probe.
For supershift analysis the indicated monoclonal anti-
odies (1 mg) were added together with the labeled
robe. For negative controls with irrelevant antibodies
e used the anti-c-Jun and anti-albumin monoclonal an-
ibodies.
To remove the Sp1 or p53 protein from the nuclear
xtracts, anti-Sp1 or pAb421 monoclonal antibodies (20
mg) were added, respectively, to aliquots of the examined
extract (200 mg extract protein) and the resultant immu-
ocomplexes were precipitated by protein A–Sepharose
L-4B beads (Pharmacia Biothech). The supernatant
as then examined for DNA binding as described above.
In all cases the DNA binding reaction mixtures were
ubjected to 5% polyacrylamide gel electrophoresis in
.25 3 TBE (1 3 TBE 5 89 mM Tris, 89 mM boric acid,
.5 mM EDTA, pH 8.3) at 110 V for 3–4 h at 4°C. The gel
as dried and subsequently autoradiographed on Kodak
-O-Mat S film at 270°C with intensifying screen.
estern blot analysis of Sp1 and p53 proteins
The nuclear level of Sp1 and p53 (w.t. 1 mutant) was
etermined by a semiquantitative Western blot analysis
f 100 and 200 mg of nuclear extract protein as described
by Mor-Vaknin et al. (1997), using the anti Sp1 and the
pAb421anti p53 monoclonal antibodies, respectively.
To determine the level of the w.t. versus the mutant p53
protein, aliquots of the examined nuclear extract (200 mg
rotein) were immunoprecipitated with pAb1620 or
Ab240 anti p53 antibodies (20 mg protein), respectively,
nd the immunoprecipitates were collected by protein
–Sepharose beads as described above. These precip-
tates were dissociated from the protein A–Sepharose
eads by heating at 95°C for 5 min and then subjected to
estern blot analysis with the indicated antibodies.
ince the heavy chain of the immunoprecipitating anti-
odies has the same SDS–PAGE mobility as p53, the
resence of p53 in immunoprecipitates pulled down with
ouse antibodies was determined by performing the
estern blot analysis of these precipitates with rabbit
olyclonal anti-p53 antibodies and peroxidase-conju-
ated mouse antibodies against rabbit IgG.
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